by | Nov 7, 2022 | Uncategorized
Belantamab mafodotin-blmf failed to extend PFS compared with pomalidomide and dexamethasone for adults with relapsed or refractory multiple myeloma, according to topline data from a confirmatory trial released by the agent’s manufacturer.Belantamab mafodotin-blmf...
by | Nov 4, 2022 | Uncategorized
The FDA granted breakthrough therapy designation to elranatamab for treatment of relapsed or refractory multiple myeloma.Elranatamab (Pfizer) is a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody. The agent is designed to bind to BCMA — which is...
by | Nov 3, 2022 | Uncategorized
Source: Cure Today articles Stem cell transplants may cause dysgeusia — a disorder that alters a person’s taste —in some patients with multiple myeloma, which is a type of blood cancer. This disorder may have a domino effect on quality of life, although levels may...
by | Oct 25, 2022 | Uncategorized
The FDA granted accelerated approval to teclistamab-cqyv for treatment of certain patients of myeloma.The indication applies to use of teclistamab-cqyv (Tecvayli, Janssen Biotech) for adults with relapsed or refractory multiple myeloma who received at least four prior...
by | Oct 25, 2022 | Uncategorized
Source: Cure Today articles The FDA’s approval of Tecvayli was based on findings showing that 61.8% of patients with pretreated, relapsed/refractory myeloma responded to the drug. Read More
by | Oct 21, 2022 | Uncategorized
Novel B-cell maturation antigen-directed immunotherapies are ready to take their place as the new standard for treatment of advanced multiple myeloma, according to a panel at NCCN 2022 Annual Congress: Hematologic Malignancies.“Immunotherapy is here for multiple...
